Phase 3Recruiting

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

Sponsor
Hudson Biotech (Industry)
Enrollment
2,539 planned
Conditions
Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Interventions
Tirzepatide; Placebo; Reduced-calorie diet
Ages
adults, older adults
Registry
NCT07481747

Full record on ClinicalTrials.gov

From the registry

This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased physical activity, in adults without type 2 diabetes who have obesity or are overweight with weight-related comorbidities. The primary efficacy assessment is at Week 72. Participants with prediabetes at randomization may continue in an additional long-term treatment period to assess progression to type 2 diabetes and longer-term weight outcomes.

Primary outcomes

  • Mean percent change in body weight from randomization
  • Percentage of participants achieving ≥5% body weight reduction from randomization

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Registered

  5. Started

In the news